Rituximab for Children with Immune Thrombocytopenia: A Systematic Review

BACKGROUND: Rituximab has been widely used off-label as a second line treatment for children with immune thrombocytopenia (ITP). However, its role in the management of pediatric ITP requires clarification. To understand and interpret the available evidence, we conducted a systematic review to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yi, Zhang, Lingli, Gao, Ju, Hu, Die, Ai, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364261/
https://www.ncbi.nlm.nih.gov/pubmed/22666325
http://dx.doi.org/10.1371/journal.pone.0036698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364261/
https://www.ncbi.nlm.nih.gov/pubmed/22666325
http://dx.doi.org/10.1371/journal.pone.0036698

Ejemplares similares